Persistence and Time to Next Treatment With Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke: A Real-World Study

被引：0
|
作者：
Narezkina, Anna [1 ]
Akhter, Nausheen [2 ]
Lu, Xiaoxiao [3 ]
Emond, Bruno [4 ]
Huang, Qing [3 ]
Panjabi, Sumeet [3 ]
Hilts, Annalise [4 ]
Lu, Stephanie [5 ]
Lafeuille, Helene [4 ]
Lafeuille, Marie-Helene [4 ]
Choi, Michael [6 ]
机构：
[1] Univ Calif San Diego Hlth, San Diego, CA USA
[2] Northwestern Med, Chicago, IL USA
[3] Janssen Sci Affairs LLC, Horsham, PA USA
[4] Anal Grp Inc, Montreal, PQ, Canada
[5] Anal Grp Inc, Menlo Pk, CA USA
[6] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷
关键词：
CLL; chronic lymphocytic leukemia/small lymphocytic lymphoma; Bruton's tyrosine kinase inhibitor; time to next treatment; treatment persistence; atrial fibrillation;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CLL-390
引用
收藏
页码：S276 / S277
页数：2
相关论文
共 50 条
  • [1] Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke
    Narezkina, Anna
    Akhter, Nausheen
    Lu, Xiaoxiao
    Emond, Bruno
    Panjabi, Sumeet
    Forbes, Shaun P.
    Hilts, Annalise
    Liu, Stephanie
    Lafeuille, Marie-Helene
    Lefebvre, Patrick
    Huang, Qing
    Choi, Michael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (11) : E959 - E971
  • [2] Real-World Dosing Patterns and Time to Next Treatment for Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With or Without Ibrutinib Dose Reduction Following an Adverse Event
    Shadman, Mazyar
    Srivastava, Bhavini P.
    Patel, Sima
    Saifan, Chadi
    Salkar, Monika
    Emond, Bruno
    Gogna, Priyanka
    Manceur, Ameur M.
    Lafeuille, Marie-Helene
    Stephens, Deborah M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S327 - S327
  • [3] Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
    Shadman, Mazyar
    Salkar, Monika
    Srivastava, Bhavini
    Karve, Sudeep
    Emond, Bruno
    Gogna, Priyanka
    Manceur, Ameur M.
    Lafeuille, Marie-Helene
    Rava, Andrew
    Sun, Haiyan
    Howarth, Amanda
    Tomicki, Samantha
    Agatep, Barnabie
    Jones, Barton
    Franceschini, Erin
    Saifan, Chadi
    Bacchus, Shaffee
    Roeker, Lindsey
    Stephens, Deborah M.
    LEUKEMIA & LYMPHOMA, 2024, : 44 - 53
  • [4] Patient Characteristics and Time to Next Treatment With Ibrutinib and Anti-CD20 Monotherapy as First-Line Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Lu, Xiaoxiao
    He, Jinghua
    Ran, Tao
    Wu, Linda
    Panjabi, Sumeet
    Vose, Julie M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S273 - S273
  • [5] Phase I study of ibrutinib in Japanese patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma
    Shibayama, Hirohiko
    Teshima, Takanori
    Choi, Ilseung
    Hatake, Kiyohiko
    Sekiguchi, Naohiro
    Yoshinari, Nozomi
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2019, 59 (04) : 179 - 186
  • [6] Time to Next Treatment, Health Care Resource Utilization, and Costs Associated with Ibrutinib Use Among US Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Retrospective Analysis
    Huang, Qing
    Borra, Sujana
    Li, Jieni
    Wang, Li
    Shrestha, Sulena
    Sundaram, Murali
    Janjan, Nora
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (10) : 1266 - 1275
  • [7] Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib
    Jacobs, Ryan
    Lu, Xiaoxiao
    Emond, Bruno
    Morrison, Laura
    Kinkead, Frederic
    Lefebvre, Patrick
    Lafeuille, Marie-Helene
    Khan, Wasiulla
    Wu, Linda H.
    Qureshi, Zaina P.
    Levy, Moshe Yair
    FUTURE ONCOLOGY, 2024, 20 (01) : 39 - 53
  • [8] Real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia in Japan: the Orbit study
    Muta, Tsuyoshi
    Masamoto, Yosuke
    Yamamoto, Go
    Kurahashi, Shingo
    Kameoka, Yoshihiro
    Ota, Shuichi
    Matsuki, Eri
    Ozeki, Kazutaka
    Toyama, Takanori
    Takahashi, Naoki
    Kumode, Takahiro
    Aotsuka, Nobuyuki
    Yoshimura, Takuro
    Tamura, Hideto
    Omi, Ai
    Shibayama, Kazuhiro
    Watanabe, Aki
    Isobe, Yasushi
    Kojima, Kensuke
    Takizawa, Jun
    Nagai, Hirokazu
    Suzumiya, Junji
    Aoki, Sadao
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2025, 121 (02) : 161 - 173
  • [9] Real-World Adherence to First-Line Ibrutinib and Acalabrutinib Single-Agent Among Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Lu, Xiaoxiao
    Emond, Bruno
    Qureshi, Zaina
    He, Jinghua
    Qian, Yi
    Huang, Qing
    Lefebvre, Patrick
    Lafeuille, Marie-Helene
    Jacobs, Ryan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S280 - S281
  • [10] Real-World Treatment Outcomes in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Were Treated With First-Line Single-Agent Ibrutinib vs Chemoimmunotherapy
    Wang, Ruibin
    Ding, Zhijie
    Lu, Xiaoxiao
    Mavani, Heena
    He, Jinghua
    Qureshi, Zaina
    Pinilla, Javier
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S330 - S330
12345